433 related articles for article (PubMed ID: 28277622)
1. Abortifacient metapristone (RU486 derivative) interrupts CXCL12/CXCR4 axis for ovarian metastatic chemoprevention.
Zheng N; Chen J; Li T; Liu W; Liu J; Chen H; Wang J; Jia L
Mol Carcinog; 2017 Aug; 56(8):1896-1908. PubMed ID: 28277622
[TBL] [Abstract][Full Text] [Related]
2. Mifepristone inhibits ovarian cancer metastasis by intervening in SDF-1/CXCR4 chemokine axis.
Zheng N; Chen J; Liu W; Liu J; Li T; Chen H; Wang J; Jia L
Oncotarget; 2017 Aug; 8(35):59123-59135. PubMed ID: 28938623
[TBL] [Abstract][Full Text] [Related]
3. CXCR7 is not obligatory for CXCL12-CXCR4-induced epithelial-mesenchymal transition in human ovarian cancer.
Zheng N; Liu W; Chen J; Li B; Liu J; Wang J; Gao Y; Shao J; Jia L
Mol Carcinog; 2019 Jan; 58(1):144-155. PubMed ID: 30259564
[TBL] [Abstract][Full Text] [Related]
4. [Relationship between chemokine axis CXCL12-CXCR4 and epithelial ovarian cancer].
Guo Q; Wu XH; Lü YP; Yang B; Xu F; Zhang SJ
Zhonghua Yi Xue Za Zhi; 2013 Jun; 93(21):1677-80. PubMed ID: 24125682
[TBL] [Abstract][Full Text] [Related]
5. Involvement of SDF-1alpha/CXCR4 axis in the enhanced peritoneal metastasis of epithelial ovarian carcinoma.
Kajiyama H; Shibata K; Terauchi M; Ino K; Nawa A; Kikkawa F
Int J Cancer; 2008 Jan; 122(1):91-9. PubMed ID: 17893878
[TBL] [Abstract][Full Text] [Related]
6. Role of CXCL12-CXCR4 axis in ovarian cancer metastasis and CXCL12-CXCR4 blockade with AMD3100 suppresses tumor cell migration and invasion in vitro.
Liu Y; Ren CC; Yang L; Xu YM; Chen YN
J Cell Physiol; 2019 Apr; 234(4):3897-3909. PubMed ID: 30191987
[TBL] [Abstract][Full Text] [Related]
7. Metapristone (RU486 derivative) inhibits cell proliferation and migration as melanoma metastatic chemopreventive agent.
Zheng N; Chen J; Liu W; Wang J; Liu J; Jia L
Biomed Pharmacother; 2017 Jun; 90():339-349. PubMed ID: 28376402
[TBL] [Abstract][Full Text] [Related]
8. Co-delivery of sorafenib and metapristone encapsulated by CXCR4-targeted PLGA-PEG nanoparticles overcomes hepatocellular carcinoma resistance to sorafenib.
Zheng N; Liu W; Li B; Nie H; Liu J; Cheng Y; Wang J; Dong H; Jia L
J Exp Clin Cancer Res; 2019 May; 38(1):232. PubMed ID: 31151472
[TBL] [Abstract][Full Text] [Related]
9. Pharmacoproteomic analysis reveals that metapristone (RU486 metabolite) intervenes E-cadherin and vimentin to realize cancer metastasis chemoprevention.
Yu S; Yan C; Yang X; He S; Liu J; Qin C; Huang C; Lu Y; Tian Z; Jia L
Sci Rep; 2016 Mar; 6():22388. PubMed ID: 26932781
[TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo efficacy and safety evaluation of metapristone and mifepristone as cancer metastatic chemopreventive agents.
Wang J; Chen J; Zhu Y; Zheng N; Liu J; Xiao Y; Lu Y; Dong H; Xie J; Yu S; Shao J; Jia L
Biomed Pharmacother; 2016 Mar; 78():291-300. PubMed ID: 26898454
[TBL] [Abstract][Full Text] [Related]
11. CXCL12-CXCR4 Axis Promotes Proliferation, Migration, Invasion, and Metastasis of Ovarian Cancer.
Guo Q; Gao BL; Zhang XJ; Liu GC; Xu F; Fan QY; Zhang SJ; Yang B; Wu XH
Oncol Res; 2014; 22(5-6):247-58. PubMed ID: 26629936
[TBL] [Abstract][Full Text] [Related]
12. Metapristone suppresses non-small cell lung cancer proliferation and metastasis via modulating RAS/RAF/MEK/MAPK signaling pathway.
Zheng G; Shen Z; Chen H; Liu J; Jiang K; Fan L; Jia L; Shao J
Biomed Pharmacother; 2017 Jun; 90():437-445. PubMed ID: 28391165
[TBL] [Abstract][Full Text] [Related]
13. [Effect of chemokine CXCL12 and its receptor CXCR4 on proliferation, migration and invasion of epithelial ovarian cancer cells].
Jiang YP; Wu XH; Xing HY; DU XY
Zhonghua Fu Chan Ke Za Zhi; 2007 Jun; 42(6):403-7. PubMed ID: 17697603
[TBL] [Abstract][Full Text] [Related]
14. Involvement of autocrine CXCL12/CXCR4 system in the regulation of ovarian carcinoma cell invasion.
Miyanishi N; Suzuki Y; Simizu S; Kuwabara Y; Banno K; Umezawa K
Biochem Biophys Res Commun; 2010 Dec; 403(1):154-9. PubMed ID: 21059341
[TBL] [Abstract][Full Text] [Related]
15. Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer.
Scotton CJ; Wilson JL; Scott K; Stamp G; Wilbanks GD; Fricker S; Bridger G; Balkwill FR
Cancer Res; 2002 Oct; 62(20):5930-8. PubMed ID: 12384559
[TBL] [Abstract][Full Text] [Related]
16. Role of CXCL12 in metastasis of human ovarian cancer.
Jiang YP; Wu XH; Xing HY; DU XY
Chin Med J (Engl); 2007 Jul; 120(14):1251-5. PubMed ID: 17697577
[TBL] [Abstract][Full Text] [Related]
17. Imaging CXCL12-CXCR4 signaling in ovarian cancer therapy.
Salomonnson E; Stacer AC; Ehrlich A; Luker KE; Luker GD
PLoS One; 2013; 8(1):e51500. PubMed ID: 23372646
[TBL] [Abstract][Full Text] [Related]
18. The inhibitory effect of doxycycline on cisplatin-sensitive and -resistant epithelial ovarian cancer.
Wu W; Yu LH; Ma B; Xu MJ
PLoS One; 2014; 9(3):e89841. PubMed ID: 24598933
[TBL] [Abstract][Full Text] [Related]
19. CXCL12/CXCR4 Axis-Targeted Dual-Functional Nano-Drug Delivery System Against Ovarian Cancer.
Xue J; Li R; Gao D; Chen F; Xie H
Int J Nanomedicine; 2020; 15():5701-5718. PubMed ID: 32848392
[TBL] [Abstract][Full Text] [Related]
20. Modulating the interaction of CXCR4 and CXCL12 by low-molecular-weight heparin inhibits hepatic metastasis of colon cancer.
Ma L; Qiao H; He C; Yang Q; Cheung CH; Kanwar JR; Sun X
Invest New Drugs; 2012 Apr; 30(2):508-17. PubMed ID: 21080209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
